Used in research as a potent and selective inhibitor of the epidermal growth factor receptor (EGFR), particularly effective against mutant forms associated with non-small cell lung cancer (NSCLC). Shows high activity against EGFR T790M and C797S mutations, which are linked to resistance to earlier generations of EGFR inhibitors. Enables the study of signaling pathways in cancer cells and supports the development of next-generation targeted therapies. Due to its ability to cross the blood-brain barrier, it is also investigated for treating brain metastases of lung cancer. Primarily utilized in preclinical studies for evaluating antitumor efficacy and pharmacokinetic profiles.